A phase III, randomized, double-blinded, multi-center, study to assess the efficacy of docetaxel (Taxotere) in combination with ZD6474 (Zactima) versus docetaxel (Taxotere) with placebo in subjects with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy

Trial Profile

A phase III, randomized, double-blinded, multi-center, study to assess the efficacy of docetaxel (Taxotere) in combination with ZD6474 (Zactima) versus docetaxel (Taxotere) with placebo in subjects with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Vandetanib (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ZODIAC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 09 Jul 2010 Status changed from active, no longer recruiting to completed.
    • 01 Jul 2010 Staus change from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top